^
Association details:
| Biomarker: | EML4-ALK fusion + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Special issue “The advance of solid tumor research in China”: Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China
Published date:
05/17/2022
Excerpt:
Patients with advanced non-small-cell lung cancer (NSCLC) and EML4–ALK fusion were enrolled...The primary endpoints were objective response rate (ORR) and progression-free survival (PFS) to alectinib.…we found that “crizotinib pretreatment”, “liver metastasis”, and “TP53 co-mutation” were individually associated with shorter PFS in alectinib treatment.
DOI:
https://doi.org/10.1002/ijc.34123
